REVTORPYK™: A New FDA Approval for Gedatolisib/HPBCD composition
A new chapter in targeted cancer therapy On July 14, 2026, the U.S. FDA approved REVTORPYK™ (gedatolisib), developed by Celcuity,
Tag: gedatolisib
A forum for researchers, students and applicants in the field of cyclodextrin technology